185 related articles for article (PubMed ID: 35163589)
21. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M
Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793
[TBL] [Abstract][Full Text] [Related]
22. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
[TBL] [Abstract][Full Text] [Related]
23. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells.
Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C
Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918
[TBL] [Abstract][Full Text] [Related]
24. HCV core protein-induced upregulation of microRNA-196a promotes aberrant proliferation in hepatocellular carcinoma by targeting FOXO1.
Xu H; Li G; Yue Z; Li C
Mol Med Rep; 2016 Jun; 13(6):5223-9. PubMed ID: 27108614
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.
Wang K; Liang Q; Wei L; Zhang W; Zhu P
Tumour Biol; 2016 Mar; 37(3):3823-30. PubMed ID: 26474589
[TBL] [Abstract][Full Text] [Related]
26. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
27. A novel anticancer agent, SKLB70359, inhibits human hepatic carcinoma cells proliferation via G0/G1 cell cycle arrest and apoptosis induction.
Dai XY; Zeng XX; Peng F; Han YY; Lin HJ; Xu YZ; Zhou T; Xie G; Deng Y; Mao YQ; Yu LT; Yang L; Zhao YL
Cell Physiol Biochem; 2012; 29(1-2):281-90. PubMed ID: 22415097
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of hepatocellular carcinoma-specific antitumor activity of the novel thienopyridine derivative TP58.
Zhou R; Huang WJ; Guo ZY; Li L; Zeng XR; Deng YQ; Hu FY; Tong AP; Yang L; Yang JL
Oncol Rep; 2012 Jul; 28(1):225-31. PubMed ID: 22552608
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma.
Teufel M; Seidel H; Köchert K; Meinhardt G; Finn RS; Llovet JM; Bruix J
Gastroenterology; 2019 May; 156(6):1731-1741. PubMed ID: 30738047
[TBL] [Abstract][Full Text] [Related]
30. MicroRNA-188-5p suppresses tumor cell proliferation and metastasis by directly targeting FGF5 in hepatocellular carcinoma.
Fang F; Chang RM; Yu L; Lei X; Xiao S; Yang H; Yang LY
J Hepatol; 2015 Oct; 63(4):874-85. PubMed ID: 25998163
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
32. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
34. Sirt3 promotes hepatocellular carcinoma cells sensitivity to regorafenib through the acceleration of mitochondrial dysfunction.
Wang R; Liu Y; Mi X; Chen Q; Jiang P; Hou J; Lin Y; Li S; Ji B; Fang Y
Arch Biochem Biophys; 2020 Aug; 689():108415. PubMed ID: 32562663
[TBL] [Abstract][Full Text] [Related]
35. Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Sasaki R; Kanda T; Fujisawa M; Matsumoto N; Masuzaki R; Ogawa M; Matsuoka S; Kuroda K; Moriyama M
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397371
[TBL] [Abstract][Full Text] [Related]
36. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma.
Yu CC; Huang SY; Chang SF; Liao KF; Chiu SC
Molecules; 2020 May; 25(10):. PubMed ID: 32466169
[TBL] [Abstract][Full Text] [Related]
37. Protein phosphatase 2A-B55δ enhances chemotherapy sensitivity of human hepatocellular carcinoma under the regulation of microRNA-133b.
Zhuang Q; Zhou T; He C; Zhang S; Qiu Y; Luo B; Zhao R; Liu H; Lin Y; Lin Z
J Exp Clin Cancer Res; 2016 Apr; 35():67. PubMed ID: 27074866
[TBL] [Abstract][Full Text] [Related]
38. PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27
Tuo L; Xiang J; Pan X; Hu J; Tang H; Liang L; Xia J; Hu Y; Zhang W; Huang A; Wang K; Tang N
J Exp Clin Cancer Res; 2019 Feb; 38(1):50. PubMed ID: 30717766
[TBL] [Abstract][Full Text] [Related]
39. Long noncoding RNA RP11-909N17.2 promotes proliferation, invasion, and migration of hepatocellular carcinoma by regulating microRNA-767-3p.
Liu Q; Dai SJ; Dong L; Li H
Biochem Cell Biol; 2020 Dec; 98(6):709-718. PubMed ID: 33210543
[TBL] [Abstract][Full Text] [Related]
40. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era.
Juengpanich S; Topatana W; Lu C; Staiculescu D; Li S; Cao J; Lin J; Hu J; Chen M; Chen J; Cai X
Int J Cancer; 2020 Oct; 147(7):1778-1792. PubMed ID: 32162677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
